Systemic Lupus Erythematosus

Status Recruiting

Clinical Trial Summary

Systemic lupus erythematosus (SLE) is a chronic autoimmune and inflammatory disease. The pathogenesis of SLE results from interactions between genes, hormones, and the environment; however, the exact etiology is unknown. SLE can affect many organs and systems, including the musculoskeletal, hematological, renal, neuropsychiatric, cardiovascular and pulmonary systems, and skin. Non-specific general complaints such as malaise, fatigue, arthralgia, anxiety, depression, fever, and weight loss are evident at the onset of the disease and during the activation periods. Patients experience hopelessness due to the complexity of the symptoms and the chronic and progressive nature of the disease, and they experience deterioration in their quality of life due to the interaction of anxiety and depression findings with other symptoms. SLE is a difficult disease to manage because of the different organ and system involvement processes. In addition, these symptoms of the disease and the nature of chronic pain, including central sensitization, cause it to accompany a process that is affected by the mood of the person. Some patients present to a rheumatologist with mild symptoms, while others may present with severe, life-threatening symptoms. The onset of the disease before the age of 18 is defined as childhood onset (juvenile). Childhood-onset SLE accounts for approximately 1/5 of SLE patients. It is known that the main mechanism in the formation of the disease is the production of more than one autoantibody. Although childhood SLE (jSLE) appears to be basically the same disease with similar etiology, pathogenesis, and laboratory findings as in adults, there are differences in the frequency and severity of clinical manifestations. In this respect, the clearest finding is that children with SLE have greater disease severity and earlier disease-related organ damage than adults with SLE. Studies on the disease show that patients with jSLE have not only physical but also cognitive effects. The aim of our study is to examine the effects of exercises applied with a dual-task approach on patients' physical and cognitive status in jSLE cases.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05984316
Study type	Interventional
Source	Biruni University
Contact	eylul pinar kisa
Phone	05321307023
Email	eylulpnr93@gmail.com
Status	Recruiting
Phase	N/A
Start date	August 2, 2023
Completion date	December 5, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05077501` - Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ACD856	Phase 1
Recruiting	`NCT04562844` - Assessment and Rehabilitation of Social Cognition in People With Traumatic Brain Injury	N/A
Not yet recruiting	`NCT05490628` - The Effects of Cognitive Rehabilitation on Motor Performance, Balance and Fear of Falling in Stroke Patients	N/A
Active, not recruiting	`NCT05111275` - Cognitive Exercises in Survivors of a Prolonged ICU Stay.	N/A
Recruiting	`NCT05201534` - Interventions in Mathematics and Cognitive Skills	N/A
Recruiting	`NCT05464472` - Impact of Transcatheter Aortic Valve Implantation (TAVI) on Cognitive Functions
Not yet recruiting	`NCT06357195` - DIAMOND-Lewy Guidelines for Antipsychotic Use in Older Patients
Recruiting	`NCT05886114` - A Multi-domain Lifestyle Intervention Among Aged Community-residents in Zhejiang, China	N/A
Withdrawn	`NCT04019665` - Self-screening of Cognitive Impairment in Primary Care	N/A
Completed	`NCT00240695` - A Follow-up Study to Assess Safety and Tolerability of Galantamine Treatment in Individuals With Mild Cognitive Impairment	Phase 3
Completed	`NCT04219774` - NeuroCognition After Carotid Recanalization	Phase 2
Not yet recruiting	`NCT06268080` - Depth of Anesthesia on Postoperative Delirium and Cognitive After Surgery	N/A
Completed	`NCT00695136` - The Effect of Donepezil (Aricept(Registered Trademark)) on REM Sleep in Children With Autism	Phase 1/Phase 2
Recruiting	`NCT04911738` - VIrtual Reality Glasses Use to Improve Lateropulsion and the Post-stroke Postural Vertical	N/A
Withdrawn	`NCT01668758` - fMRI and NIRS Imaging for Traumatic Brain Injury	N/A
Completed	`NCT05783830` - Study Evaluating the Pharmacokinetics of a Single Microdose of ACD856	Early Phase 1
Recruiting	`NCT06186102` - Polyamine Treatment in Elderly Patients With Coronary Artery Disease	Phase 2
Recruiting	`NCT05322031` - The Impact of Aripiprazole Long-acting on Myelin and Cognition in the Onset of Schizophrenia	Phase 4
Completed	`NCT04210713` - Neuroimmune Dysfunction in Alcohol Use Disorder	Phase 1
Completed	`NCT05077631` - Study to Evaluate the Effects of Single Ascending Oral Doses of ACD856 on Safety, Tolerability and Pharmacokinetics	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.